Why Aptose Biosciences Plunged 45% Yesterday

Aptose Biosciences (TSX:APT)(NASDAQ:APTO) results for its leukemia drug were met with a poor reaction, sending shares down 45%.

| More on:

Aptose Biosciences (TSX:APT)(NASDAQ:APTO) shares crashed 45% on Tuesday after results from its leukemia trial were met with a less-than-ideal reaction.

What happened?

The biotechnology company focused on oncology reported its oral, once-daily myeloid kinome inhibitor (MKI) phase-one-of-two study. The company believes it showed “meaningful benefit in all responders” in the 34-patient study. It’s a difficult area of study, as acute myelogenous leukemia (ACL) relapses are incredibly difficult to treat.

Its current trial, named luxeptinib, aims at creating a “next generation” formula, to “reduce pill burden, improve absorption, and increase exposure.” The new formula aims to begin testing by the first half of 2022.

The news became public on Monday evening, sending shares in a downward spiral almost immediately. Shares reached a trough price, down 45% on Tuesday. Shares currently trade at $1.44 as of writing.

So what?

This new study continues the bad share news for Aptose, despite analysts continuing to recommend it as a strong buy. It seems that investors don’t want to wait for action and remain unconvinced for a while now. The last report back in June was also met with lukewarm results.

The problem is that it’s been far too much waiting for investors regarding Aptose. Everyone wants the next big thing after the COVID-19 vaccine. A treatment for cancer would certainly be a great place to look. However, Aptose continues to see more trials and small results.

Now what?

Analysts are of mixed minds when it comes to Aptose. On the one hand, it could be a good momentum buy if you’re watching it like a hawk. On the other hand, it’s not valuable at the moment. Its fundamentals are weak, with a -1.93 EV/EBITDA and price-to-book ratio of two. Further, it continues to operate at a loss, with its most recent earnings coming in at a loss of $55 million. And that loss has grown larger and larger as the quarters continue on.

If Aptose can’t convince investors that its next drug is worth the wait soon, it may be out of long-term luck. So, I wouldn’t look at this week’s collapse in share price as an opportunity. I’d definitely wait and see what happened in 2022 before buying even a share of Aptose.

Shares of Aptose are down 75% year to date.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

coins jump into piggy bank
Tech Stocks

2 Top TSX Stocks to Buy and Hold in Your TFSA

Here's why TFSA investors should consider owning top TSX stocks such as DCBO in their equity portfolio right now.

Read more »

Silhouette of bull in front of setting sun
Energy Stocks

I’m Growing Very Bullish on This Canadian Energy Stock

Let's dive into what to make of Suncor's (TSX:SU) recent moves, and whether this top Canadian energy stock has more…

Read more »

Man in fedora smiles into camera
Dividend Stocks

Build Passive Income in Retirement With These 3 Canadian Dividend Gems

Let's dive into whether Enbridge (TSX:ENB), Sun Life Financial (TSX:SLF), and Bank of Nova Scotia (TSX:BNS) are dividend stocks worth…

Read more »

A plant grows from coins.
Investing

What Are Some High-Growth Canadian Stocks to Buy Now?

These high-growth Canadian stocks have delivered exceptional capital gains, and their impressive upward trajectory is unlikely to slow down.

Read more »

money goes up and down in balance
Dividend Stocks

3 Stocks Yielding Up to 8.5% to Buy and Hold

Investing in high dividend TSX stocks such as MCAN can help you generate a steady stream of passive income in…

Read more »

Man holds Canadian dollars in differing amounts
Dividend Stocks

Here’s How I’m Boosting My Annual Passive Income to +$6,000 Next Year

Dividend stocks like Toronto-Dominion Bank (TSX:TD) will add to my passive income in 2026.

Read more »

Stethoscope with dollar shaped cord
Tech Stocks

1 Canadian Healthcare Stock That’s My Defensive Growth Play

Well Health Technologies is seeing rapid growth as it brings the benefits of technology to the healthcare sector.

Read more »

Bitcoin
Stocks for Beginners

2 TSX Stocks With Huge Upside as the U.S. Dollar Strengthens

Investors wanting to protect their future need safe Canadian stocks, like these two on the TSX today.

Read more »